Dietary Vitamin D 3 Supplementation at 10× the Adequate Intake Improves Functional Capacity in the G93A Transgenic Mouse Model of ALS, a Pilot Study

CNS Neuroscience and Therapeutics

Volumn 18, Issue 7, 2012, Pages 547-557

  Gianforcaro, Alexandro ^a,b   Hamadeh, Mazen J ^a,b,c  

^a York University   (Canada)

^b YORK UNIVERSITY   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

Amyotrophic lateral sclerosis; G93A mice; Lifespan; Motor performance; Paw grip endurance; Vitamin D

Indexed keywords

COLECALCIFEROL; SOD1 G93A PROTEIN; SUPEROXIDE DISMUTASE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIETARY INTAKE; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; FEMALE; FUNCTIONAL STATUS; GRIP STRENGTH; LIFESPAN; MALE; MOTOR PERFORMANCE; MOUSE; NONHUMAN; PILOT STUDY; VITAMIN SUPPLEMENTATION; ANIMAL; C57BL MOUSE; CONVALESCENCE; DIET SUPPLEMENTATION; DIET THERAPY; DISEASE MODEL; DRUG EFFECT; GENETICS; HUMAN; SEX DIFFERENCE; TRANSGENIC MOUSE; UPREGULATION;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; CHOLECALCIFEROL; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PILOT PROJECTS; RECOVERY OF FUNCTION; SEX FACTORS; SUPEROXIDE DISMUTASE; UP-REGULATION;

EID: 84863525742     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2012.00316.x     Document Type: Article

References (47)

1. Turner BJ, Talbot K. Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS. Prog Neurobiol 2008;85:94-134.
2. Bruijn LI, Miller TM, Cleveland DW. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci 2004;27:723-49.
3. Gurney ME, Pu H, Chiu AY, et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science New York, NY 1994;264:1772-1775.
4. Gurney ME. Transgenic-mouse model of amyotrophic lateral sclerosis. N Engl J Med 1994;331:1721-1722.
5. Patel BP, Hamadeh MJ. Nutritional and exercise-based interventions in the treatment of amyotrophic lateral sclerosis. Clin Nutr 2009;28:604-617.
6. Hamadeh MJ, Rodriguez MC, Kaczor JJ, Tarnopolsky MA. Caloric restriction transiently improves motor performance but hastens clinical onset of disease in the Cu/Zn-superoxide dismutase mutant G93A mouse. Muscle Nerve 2005;31:214-220.
7. Hamadeh MJ, Tarnopolsky MA. Transient caloric restriction in early adulthood hastens disease endpoint in male, but not female, Cu/Zn-SOD mutant G93A mice. Muscle Nerve 2006;34:709-719.
8. Patel BP, Safdar A, Raha S, Tarnopolsky MA, Hamadeh MJ. Caloric restriction shortens lifespan through an increase in lipid peroxidation, inflammation and apoptosis in the G93A mouse, an animal model of ALS. PLoS One 2010;5:e9386.
9. Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev (Online) 2007:CD001447.
10. Deng Y, Xu Z, Xu B, et al. The protective effect of riluzole on manganese caused disruption of glutamate-glutamine cycle in rats. Brain Res 2009;1289:106-117.
11. Hamden K, Carreau S, Jamoussi K, et al. 1Alpha, 25 dihydroxyvitamin D3: Therapeutic and preventive effects against oxidative stress, hepatic, pancreatic and renal injury in alloxan-induced diabetes in rats. J Nutr Sci Vitaminol 2009;55:215-222.
12. Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr 2006;83:754-759.
13. Taniura H, Ito M, Sanada N, et al. Chronic vitamin D3 treatment protects against neurotoxicity by glutamate in association with upregulation of vitamin D receptor mRNA expression in cultured rat cortical neurons. J Neurosci Res 2006;83:1179-1189.
14. Naveilhan P, Neveu I, Wion D, Brachet P. 1, 25-Dihydroxyvitamin D3, an inducer of glial cell line-derived neurotrophic factor. Neuroreport 1996;7:2171-2175.
15. Veenstra TD, Windebank AJ, Kumar R. 1, 25-dihydroxyvitamin D3 regulates the expression of N-myc, c-myc, protein kinase C, and transforming growth factor-beta2 in neuroblastoma cells. Biochem Biophys Res Commun 1997;235:15-18.
16. Wang Y, Chiang YH, Su TP, et al. Vitamin D(3) attenuates cortical infarction induced by middle cerebral arterial ligation in rats. Neuropharmacology 2000;39:873-880.
17. Sanchez B, Lopez-Martin E, Segura C, Labandeira-Garcia JL, Perez-Fernandez R. 1, 25-Dihydroxyvitamin D(3) increases striatal GDNF mRNA and protein expression in adult rats. Brain Res Mol Brain Res 2002;108:143-146.
18. National Research Council. Nutrient requirements of laboratory animals. Washington, DC: National Academy Press 1995.
19. Solomon JA, Gianforcaro A, Hamadeh MJ. Vitamin D3 deficiency differentially affects functional and disease outcomes in the G93A mouse model of amyotrophic lateral sclerosis. PLoS ONE 2011;6:e29354.
20. Gianforcaro A, Solomon JA, Hamadeh MJ. Vitamin D3 at 50x AI attenuates the decline in paw grip endurance, but not disease outcomes, in the G93A mouse model of ALS, and is toxic in females. PLoS ONEMay 2012;7:e30243.
21. Solomon JA, Tarnopolsky MA, Hamadeh MJ. One universal common endpoint in mouse models of amyotrophic lateral sclerosis. PLoS ONE 2011;6:e20582.
22. Sango K, McDonald MP, Crawley JN, et al. Mice lacking both subunits of lysosomal beta-hexosaminidase display gangliosidosis and mucopolysaccharidosis. Nat Genet 1996;14:348-352.
23. Weydt P, Hong SY, Kliot M, Moller T. Assessing disease onset and progression in the SOD1 mouse model of ALS. Neuroreport 2003;14:1051-1054.
24. Andreassen OA, Jenkins BG, Dedeoglu A, et al. Increases in cortical glutamate concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementation. J Neurochem 2001;77:383-390.
25. Food and Drug Administration. Estimating the safe starting dose in clinical trials for therapeutics in adult healthy volunteers. Rockville, Maryland, USA: U.S. Food and Drug Administration. 2005.
26. Cantorna MT, Humpal-Winter J, DeLuca HF. Dietary calcium is a major factor in 1, 25-dihydroxycholecalciferol suppression of experimental autoimmune encephalomyelitis in mice. J Nutr 1999;129:1966-1971.
27. Cantorna MT, Hayes CE, DeLuca HF. 1, 25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci U S A 1996;93:7861-7864.
28. Cantorna MT, Hayes CE, DeLuca HF. 1, 25-Dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis. J Nutr 1998;128:68-72.
29. Cantorna MT, Munsick C, Bemiss C, Mahon BD. 1, 25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J Nutr 2000;130:2648-2652.
30. Bouillon R, Carmeliet G, Verlinden L, et al. Vitamin D and human health: Lessons from vitamin D receptor null mice. Endo Rev 2008;29:726-776.
31. Bischoff HA, Borchers M, Gudat F, et al. In situ detection of 1, 25-dihydroxyvitamin D3 receptor in human skeletal muscle tissue. Histochem J 2001;33:19-24.
32. Wang Y, DeLuca HF. Is the vitamin D receptor found in muscle? Endocrinology 2011;152:354-363.
33. Bischoff-Ferrari HA, Dietrich T, et al. Higher 25-hydroxyvitamin D concentrations are associated with better lower-extremity function in both active and inactive persons aged > or = 60 y. Am J Clin Nutr 2004;80:752-758.
34. Bischoff HA, Stahelin HB, Dick W, et al. Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial. J Bone Miner Res 2003;18:343-351.
35. Pfeifer M, Begerow B, Minne HW, Suppan K, Fahrleitner-Pammer A, Dobnig H. Effects of a long-term vitamin D and calcium supplementation on falls and parameters of muscle function in community-dwelling older individuals. Osteoporos Int 2009;20:315-322.
36. Broe KE, Chen TC, Weinberg J, Bischoff-Ferrari HA, Holick MF, Kiel DP. A higher dose of vitamin D reduces the risk of falls in nursing home residents: A randomized, multiple-dose study. J Am Geriatr Soc 2007;55:234-239.
37. Gordon PL, Sakkas GK, Doyle JW, Shubert T, Johansen KL. Relationship between vitamin D and muscle size and strength in patients on hemodialysis. J Ren Nutr 2007;17:397-407.
38. Verhaar HJ, Samson MM, Jansen PA, de Vreede PL, Manten JW, Duursma SA. Muscle strength, functional mobility and vitamin D in older women. Aging (Milan, Italy) 2000;12:455-460.
39. Pointon JJ, Francis MJ, Smith R. Effect of vitamin D deficiency on sarcoplasmic reticulum function and troponin C concentration of rabbit skeletal muscle. Clin Sci (Lond) 1979;57:257-63.
40. Birge SJ, Haddad JG. 25-hydroxycholecalciferol stimulation of muscle metabolism. J Clin Invest 1975;56:1100-1107.
41. de Boland AR, Albornoz LE, Boland R. The effect of cholecalciferol in vivo on proteins and lipids of skeletal muscle from rachitic chicks. Calcif Tissue Int 1983;35:798-805.
42. Nashold FE, Spach KM, Spanier JA, Hayes CE. Estrogen controls vitamin D3-mediated resistance to experimental autoimmune encephalomyelitis by controlling vitamin D3 metabolism and receptor expression. J Immunol 2009;183:3672-3681.
43. Spach KM, Hayes CE. Vitamin D3 confers protection from autoimmune encephalomyelitis only in female mice. J Immunol 2005;175:4119-4126.
44. Hathcock JN, Shao A, Vieth R, Heaney R. Risk assessment for vitamin D. Am J Clin Nutr 2007;85:6-18.
45. Holick MF. Sunlight "D"ilemma: Risk of skin cancer or bone disease and muscle weakness. Lancet 2001;357:4-6.
46. Food and Nutrition Board. Institute of medicine. Dietary reference intakes for calcium, magnesium, vitamin D, and fluoride. Washington, DC: National Academy Press. 1997.
47. Food and Nutrition Board. Dietary reference intakes for calcium and vitamin D. Washington, DC: National Academy Press. 2010.